Systematic validation of variants of unknown significance in APP, PSEN1 and PSEN2

Simon Hsu,Anna A. Pimenova,Kimberly Hayes,Juan A. Villa,Matthew J. Rosene,Madhavi Jere,Alison M. Goate,Celeste M. Karch

DOI: https://doi.org/10.1016/j.nbd.2020.104817

IF: 7.046

2020-06-01

Neurobiology of Disease

Abstract:Alzheimer's disease (AD) is a neurodegenerative disease that is clinically characterized by progressive cognitive decline. More than 200 pathogenic mutations have been identified in amyloid-β precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2). Additionally, common and rare variants occur within APP, PSEN1, and PSEN2 that may be risk factors, protective factors, or benign, non-pathogenic polymorphisms. Yet, to date, no single study has carefully examined the effect of all of the variants of unknown significance reported in APP, PSEN1 and PSEN2 on Aβ isoform levels in vitro. In this study, we analyzed Aβ isoform levels by ELISA in a cell-based system in which each reported pathogenic and risk variant in APP, PSEN1, and PSEN2 was expressed individually. In order to classify variants for which limited family history data is available, we have implemented an algorithm for determining pathogenicity using available information from multiple domains, including genetic, bioinformatic, and in vitro analyses. We identified 90 variants of unknown significance and classified 19 as likely pathogenic mutations. We also propose that five variants are possibly protective. In defining a subset of these variants as pathogenic, individuals from these families may eligible to enroll in observational studies and clinical trials.

neurosciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to systematically verify the clinical significance of variants found in Alzheimer's disease (AD) - related genes APP, PSEN1 and PSEN2. Specifically, the pathogenicity of these variants has not been clearly defined, that is, whether they will cause the disease or are just harmless polymorphisms. Due to the limited family genetic data of these variants, the researchers designed an algorithm to evaluate the pathogenicity of these variants by combining data from genetics, bioinformatics and cell experiments to achieve this goal.

The main objectives of the paper include:
1. **Evaluate the impact of variants on Aβ levels**: Through cell experiments, detect how these variants affect the levels of Aβ40 and Aβ42 to judge their potential pathogenicity.
2. **Develop and apply a new pathogenicity evaluation algorithm**: When family genetic data are lacking, use an algorithm that integrates multiple data sources (such as genetics, bioinformatics and cell experiments) to classify these variants.
3. **Identify possible protective variants**: In addition to identifying pathogenic variants, it is also hoped to find variants that may have a protective effect on AD.

Through these methods, the researchers hope to be able to classify these variants more accurately, thereby providing a basis for clinical diagnosis and treatment.